Guggenheim raised the firm’s price target on Roivant Sciences (ROIV) to $30 from $28 and keeps a Buy rating on the shares. The firm adjusted its model following Q4 earnings.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ROIV: